18 August 2020 : Clinical Research
Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
Ling Zhu12ABCDEFG, Qianwei Cui1BCEF, Ying Liu3BCEF, Zhongwei Liu1BCE, Yong Zhang1BCF, Fuqiang Liu1ACDEFG, Junkui Wang1ACDEFG*DOI: 10.12659/MSM.925114
Med Sci Monit 2020; 26:e925114
Supplementary Table 4 Multivariate COX analysis of progress to NYHA III or IV according to risk category of always b-blocker and statin treatment.
Progress to NYHA III or IV | No therapy | beta-Blocker mono-therapy | Statin mono-therapy | Co-therapy |
---|---|---|---|---|
n=139 | n=71 | n=149 | n=277 | |
Model 1a | ||||
HR (95% CI)* | 1.00 | 1.36 (0.43–4.30) | 0.26 (0.06–1.27) | 0.21 (0.05–0.80) |
value* | 0.598 | 0.097 | 0.023 | |
Model 2b | ||||
HR (95% CI)* | 1.00 | 1.18 (0.37–3.77) | 0.25 (0.05–1.21) | 0.20 (0.05–0.76) |
value* | 0.785 | 0.085 | 0.018 | |
Model 3c | ||||
HR (95% CI)* | 1.00 | 1.05 (0.32–3.38) | 0.24 (0.05–1.18) | 0.17 (0.04–0.65) |
value* | 0.942 | 0.080 | 0.010 | |
Model 4d | ||||
HR (95% CI)* | 1.00 | 1.04 (0.32–3.38) | 0.24 (0.05–1.23) | 0.17 (0.04–0.68) |
value* | 0.952 | 0.088 | 0.013 | |
* Compared with the no therapy group; a Model 1: Unadjusted; b Model 2: Multivariate adjustment was made for age, sex, smoking, body mass index; c Model 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation; d Model 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of ACEI or ARB, revascularization at baseline. There were 0 cardiovascular death, 8 myocardial infarction, and 14 stroke during the follow-up. The incidence of cardiovascular death, myocardial infarction, and stroke were low and did not allow for further analysis. CI – confidence interval; HR – hazard ratio. |